Mitsubishi UFJ Trust & Banking Corp Has $22.34 Million Holdings in Hologic, Inc. (HOLX)

Mitsubishi UFJ Trust & Banking Corp cut its holdings in Hologic, Inc. (NASDAQ:HOLX) by 7.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 608,749 shares of the medical equipment provider’s stock after selling 49,417 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned about 0.22% of Hologic worth $22,335,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Strs Ohio increased its position in shares of Hologic by 49.0% during the second quarter. Strs Ohio now owns 42,706 shares of the medical equipment provider’s stock worth $1,937,000 after purchasing an additional 14,049 shares in the last quarter. Municipal Employees Retirement System of Michigan increased its position in shares of Hologic by 27.5% during the second quarter. Municipal Employees Retirement System of Michigan now owns 24,810 shares of the medical equipment provider’s stock worth $1,126,000 after purchasing an additional 5,350 shares in the last quarter. Janney Montgomery Scott LLC increased its position in Hologic by 17.7% in the 2nd quarter. Janney Montgomery Scott LLC now owns 9,771 shares of the medical equipment provider’s stock valued at $443,000 after acquiring an additional 1,472 shares during the period. Great West Life Assurance Co. Can increased its position in Hologic by 1.2% in the 2nd quarter. Great West Life Assurance Co. Can now owns 209,607 shares of the medical equipment provider’s stock valued at $9,499,000 after acquiring an additional 2,483 shares during the period. Finally, CIBC Asset Management Inc increased its position in Hologic by 3.2% in the 2nd quarter. CIBC Asset Management Inc now owns 37,285 shares of the medical equipment provider’s stock valued at $1,692,000 after acquiring an additional 1,149 shares during the period. Institutional investors own 98.09% of the company’s stock.

Several equities analysts recently issued reports on the company. Needham & Company LLC restated a “buy” rating and issued a $48.00 price target (up previously from $46.00) on shares of Hologic in a research report on Tuesday. Piper Jaffray Companies restated a “buy” rating and issued a $48.00 price target on shares of Hologic in a research report on Thursday, November 9th. Zacks Investment Research upgraded Hologic from a “sell” rating to a “hold” rating in a research report on Tuesday, October 31st. Jefferies Group restated a “buy” rating and issued a $44.00 price target (down previously from $49.00) on shares of Hologic in a research report on Tuesday, October 10th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $45.00 price target (down previously from $48.00) on shares of Hologic in a research report on Monday, October 9th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the company. Hologic currently has an average rating of “Buy” and an average price target of $47.38.

Shares of Hologic, Inc. (NASDAQ HOLX) opened at $41.68 on Friday. Hologic, Inc. has a twelve month low of $35.76 and a twelve month high of $46.80. The firm has a market capitalization of $11,548.39, a P/E ratio of 20.74, a price-to-earnings-growth ratio of 2.03 and a beta of 0.95. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.79 and a quick ratio of 0.61.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The company had revenue of $802.90 million for the quarter, compared to analyst estimates of $792.54 million. During the same quarter in the previous year, the company earned $0.52 EPS. The firm’s revenue for the quarter was up 10.5% compared to the same quarter last year. equities research analysts forecast that Hologic, Inc. will post 2.12 earnings per share for the current fiscal year.

In other news, Director Lawrence M. Levy sold 9,596 shares of the business’s stock in a transaction that occurred on Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total transaction of $353,228.76. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Karleen Marie Oberton sold 1,023 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $39.84, for a total value of $40,756.32. The disclosure for this sale can be found here. Insiders sold a total of 28,833 shares of company stock worth $1,107,270 in the last ninety days. 0.79% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This article was originally posted by Stock Observer and is owned by of Stock Observer. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.thestockobserver.com/2017/12/08/mitsubishi-ufj-trust-banking-corp-has-22-34-million-holdings-in-hologic-inc-holx.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply